These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 23016839)

  • 1. Mapping myeloperoxidase to identify its promiscuity properties using docking and molecular dynamics simulations.
    Ramírez-Durán LA; Rosales-Hernández MC; Hernández-Rodríguez M; Mendieta-Wejebe JE; Trujillo-Ferrara J; Correa-Basurto J
    Curr Pharm Des; 2013; 19(12):2204-15. PubMed ID: 23016839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ordered cleavage of myeloperoxidase ester bonds releases active site heme leading to inactivation of myeloperoxidase by benzoic acid hydrazide analogs.
    Huang J; Smith F; Panizzi P
    Arch Biochem Biophys; 2014 Apr; 548():74-85. PubMed ID: 24632143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of Myeloperoxidase- and Neutrophil-Mediated Hypochlorous Acid Formation in Vitro and Endothelial Cell Injury by (-)-Epigallocatechin Gallate.
    Tian R; Ding Y; Peng YY; Lu N
    J Agric Food Chem; 2017 Apr; 65(15):3198-3203. PubMed ID: 28361543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel bis-arylalkylamines as myeloperoxidase inhibitors: Design, synthesis, and structure-activity relationship study.
    Aldib I; Gelbcke M; Soubhye J; Prévost M; Furtmüller PG; Obinger C; Elfving B; Alard IC; Roos G; Delporte C; Berger G; Dufour D; Zouaoui Boudjeltia K; Nève J; Dufrasne F; Van Antwerpen P
    Eur J Med Chem; 2016 Nov; 123():746-762. PubMed ID: 27537923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent reversible inhibition of myeloperoxidase by aromatic hydroxamates.
    Forbes LV; Sjögren T; Auchère F; Jenkins DW; Thong B; Laughton D; Hemsley P; Pairaudeau G; Turner R; Eriksson H; Unitt JF; Kettle AJ
    J Biol Chem; 2013 Dec; 288(51):36636-47. PubMed ID: 24194519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rational drug design applied to myeloperoxidase inhibition.
    Van Antwerpen P; Zouaoui Boudjeltia K
    Free Radic Res; 2015 Jun; 49(6):711-20. PubMed ID: 25788127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the binding and reactivity of plant and mammalian peroxidases to indole derivatives by computational docking.
    Hallingbäck HR; Gabdoulline RR; Wade RC
    Biochemistry; 2006 Mar; 45(9):2940-50. PubMed ID: 16503648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The soluble curcumin derivative NDS27 inhibits superoxide anion production by neutrophils and acts as substrate and reversible inhibitor of myeloperoxidase.
    Franck T; Aldib I; Zouaoui Boudjeltia K; Furtmüller PG; Obinger C; Neven P; Prévost M; Soubhye J; Van Antwerpen P; Mouithys-Mickalad A; Serteyn D
    Chem Biol Interact; 2019 Jan; 297():34-43. PubMed ID: 30342014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting protein tyrosine phosphatase to unravel possible inhibitors for Streptococcus pneumoniae using molecular docking, molecular dynamics simulations coupled with free energy calculations.
    Zaman Z; Khan S; Nouroz F; Farooq U; Urooj A
    Life Sci; 2021 Jan; 264():118621. PubMed ID: 33164832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inactivation of myeloperoxidase by benzoic acid hydrazide.
    Huang J; Smith F; Panizzi JR; Goodwin DC; Panizzi P
    Arch Biochem Biophys; 2015 Mar; 570():14-22. PubMed ID: 25688920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Shape-based virtual screening, docking, and molecular dynamics simulations to identify Mtb-ASADH inhibitors.
    Kumar R; Garg P; Bharatam PV
    J Biomol Struct Dyn; 2015; 33(5):1082-93. PubMed ID: 24875451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of chemical features of potent myeloperoxidase inhibitors.
    Soubhye J; Meyer F; Furtmüller P; Obinger C; Dufrasne F; Antwerpen PV
    Future Med Chem; 2016 Jul; 8(11):1163-77. PubMed ID: 27402298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of myeloperoxidase activity by the alkaloids of Peganum harmala L. (Zygophyllaceae).
    Bensalem S; Soubhye J; Aldib I; Bournine L; Nguyen AT; Vanhaeverbeek M; Rousseau A; Boudjeltia KZ; Sarakbi A; Kauffmann JM; Nève J; Prévost M; Stévigny C; Maiza-Benabdesselam F; Bedjou F; Van Antwerpen P; Duez P
    J Ethnopharmacol; 2014 Jun; 154(2):361-9. PubMed ID: 24746482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chalcones and their B-aryl analogues as myeloperoxidase inhibitors: In silico, in vitro and ex vivo investigations.
    Santos MBD; Carvalho Marques B; Miranda Ayusso G; Rocha Garcia MA; Chiquetto Paracatu L; Pauli I; Silva Bolzani V; Defini Andricopulo A; Farias Ximenes V; Zeraik ML; Regasini LO
    Bioorg Chem; 2021 May; 110():104773. PubMed ID: 33744807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computational sampling of a cryptic drug binding site in a protein receptor: explicit solvent molecular dynamics and inhibitor docking to p38 MAP kinase.
    Frembgen-Kesner T; Elcock AH
    J Mol Biol; 2006 May; 359(1):202-14. PubMed ID: 16616932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitive Effects of Quercetin on Myeloperoxidase-Dependent Hypochlorous Acid Formation and Vascular Endothelial Injury.
    Lu N; Sui Y; Tian R; Peng YY
    J Agric Food Chem; 2018 May; 66(19):4933-4940. PubMed ID: 29708335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and structure activity relationships of 7-benzyl triazolopyridines as stable, selective, and reversible inhibitors of myeloperoxidase.
    Shaw SA; Vokits BP; Dilger AK; Viet A; Clark CG; Abell LM; Locke GA; Duke G; Kopcho LM; Dongre A; Gao J; Krishnakumar A; Jusuf S; Khan J; Spronk SA; Basso MD; Zhao L; Cantor GH; Onorato JM; Wexler RR; Duclos F; Kick EK
    Bioorg Med Chem; 2020 Nov; 28(22):115723. PubMed ID: 33007547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methoxyphenol derivatives as reversible inhibitors of myeloperoxidase as potential antiatherosclerotic agents.
    Jayaraj P; Narasimhulu CA; Maiseyeu A; Durairaj R; Rao S; Rajagopalan S; Parthasarathy S; Desikan R
    Future Med Chem; 2020 Jan; 12(2):95-110. PubMed ID: 31769316
    [No Abstract]   [Full Text] [Related]  

  • 19. Discovery of novel inhibitors of Mycobacterium tuberculosis MurG: homology modelling, structure based pharmacophore, molecular docking, and molecular dynamics simulations.
    Saxena S; Abdullah M; Sriram D; Guruprasad L
    J Biomol Struct Dyn; 2018 Sep; 36(12):3184-3198. PubMed ID: 28948866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploitation of the unusual thermodynamic properties of human myeloperoxidase in inhibitor design.
    Jantschko W; Furtmüller PG; Zederbauer M; Neugschwandtner K; Lehner I; Jakopitsch C; Arnhold J; Obinger C
    Biochem Pharmacol; 2005 Apr; 69(8):1149-57. PubMed ID: 15794935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.